VICENTINI, Caterina
 Distribuzione geografica
Continente #
EU - Europa 2.658
NA - Nord America 2.518
AS - Asia 1.806
SA - Sud America 215
AF - Africa 38
OC - Oceania 8
Totale 7.243
Nazione #
US - Stati Uniti d'America 2.463
RU - Federazione Russa 1.035
CN - Cina 646
SG - Singapore 604
GB - Regno Unito 495
IT - Italia 313
DE - Germania 182
VN - Vietnam 182
BR - Brasile 165
HK - Hong Kong 148
SE - Svezia 140
IE - Irlanda 136
FR - Francia 118
FI - Finlandia 88
KR - Corea 54
CA - Canada 32
BD - Bangladesh 25
IN - India 24
ES - Italia 23
UA - Ucraina 23
JP - Giappone 22
NL - Olanda 21
BE - Belgio 18
TR - Turchia 17
AT - Austria 16
PL - Polonia 16
EC - Ecuador 15
AR - Argentina 13
ID - Indonesia 13
MX - Messico 12
IQ - Iraq 11
MA - Marocco 9
AU - Australia 8
NG - Nigeria 8
UZ - Uzbekistan 8
CH - Svizzera 6
CL - Cile 5
CO - Colombia 5
IR - Iran 5
LT - Lituania 5
VE - Venezuela 5
ZA - Sudafrica 5
CZ - Repubblica Ceca 4
ET - Etiopia 4
JO - Giordania 4
KG - Kirghizistan 4
MY - Malesia 4
PH - Filippine 4
PK - Pakistan 4
SA - Arabia Saudita 4
TW - Taiwan 4
AL - Albania 3
AZ - Azerbaigian 3
CR - Costa Rica 3
NP - Nepal 3
RS - Serbia 3
TG - Togo 3
BO - Bolivia 2
BY - Bielorussia 2
DZ - Algeria 2
GR - Grecia 2
HR - Croazia 2
IL - Israele 2
KE - Kenya 2
NI - Nicaragua 2
OM - Oman 2
PE - Perù 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BG - Bulgaria 1
BJ - Benin 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GE - Georgia 1
HU - Ungheria 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
LV - Lettonia 1
ML - Mali 1
NO - Norvegia 1
PA - Panama 1
PT - Portogallo 1
PY - Paraguay 1
RE - Reunion 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 7.243
Città #
Southend 440
Moscow 357
Singapore 332
Chandler 319
Ashburn 309
San Jose 240
Dallas 176
Verona 167
Beijing 144
Hong Kong 144
Dublin 127
Woodbridge 112
Ann Arbor 89
New York 88
Jacksonville 79
Munich 62
Council Bluffs 58
Houston 57
Ho Chi Minh City 53
The Dalles 53
Los Angeles 50
Shenyang 47
Lawrence 40
Princeton 40
Jinan 38
Hanoi 37
Wilmington 34
Dearborn 32
Helsinki 30
Nanjing 25
Tianjin 25
Hebei 24
Redmond 23
Tokyo 22
Turku 22
São Paulo 21
Changsha 20
Milan 20
Buffalo 19
Brussels 18
Columbus 18
Nanchang 18
Ningbo 18
Redondo Beach 18
Zhengzhou 18
Santa Clara 16
Frankfurt am Main 15
Guangzhou 15
Orem 15
Denver 14
Hangzhou 14
Sindelfingen 13
Haikou 12
London 12
Taiyuan 12
Warsaw 12
Brooklyn 11
Vienna 11
Amsterdam 10
Madrid 10
Montreal 10
Seoul 10
Bologna 9
Jiaxing 9
Paris 9
Poplar 9
Rome 9
Seattle 9
Stockholm 9
Abuja 8
Ankara 8
Atlanta 8
Biên Hòa 8
Chennai 8
Da Nang 8
San Francisco 8
Dong Ket 7
Jakarta 7
Norwalk 7
Piscataway 7
Taizhou 7
Tashkent 7
Barnet 6
Chicago 6
Kent 6
Mexico City 6
Redwood City 6
Toronto 6
Washington 6
Baghdad 5
Falkenstein 5
Fuzhou 5
Guayaquil 5
Haiphong 5
Hải Dương 5
Johannesburg 5
New Delhi 5
Nuremberg 5
Zurich 5
Addis Ababa 4
Totale 4.552
Nome #
Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53 286
Whole-genome landscape of pancreatic neuroendocrine tumours 281
Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression 230
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 219
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 219
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 203
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 194
Evaluation of cell-free DNA as a biomarker for pancreatic malignancies 191
Reporting tumor molecular heterogeneity in histopathological diagnosis 190
Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers 188
RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes 185
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma 185
Comparative Lesions Analysis Through a Targeted Sequencing Approach 185
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 183
Break-apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangements 182
Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract. 179
Fhit down-regulation is an early event in pancreatic carcinogenesis 177
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 177
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 177
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas 173
COVID-19 seroprevalence amongst healthcare workers: potential biases in estimating infection prevalence 172
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 171
ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance 167
Loss of FGFR4 promotes the malignant phenotype of PDAC 166
Exosomal miRNA signatures of pancreatic lesions 161
Poorly Cohesive Gastric Cancers Showing the Transcriptomic Hallmarks of Epithelial-Mesenchymal Transition Behave Aggressively 159
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer 152
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 150
Long-term organoid culture of a small intestinal neuroendocrine tumor 147
Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumours display divergent genomic and transcriptomic profiles 146
Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer 139
A differentially expressed set of micrornas in cerebro-spinal fluid (CSF) can diagnose CNS malignancies 138
Current role of non-coding RNAs in the clinical setting 134
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 131
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells 130
Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis 124
MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer 123
Lamc2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth 122
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 119
MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7 117
Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers 108
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine 95
miR-15b/16-2 deletion promotes B-cell malignancies 93
MCL1 as putative target in pancreatoblastoma 93
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage 70
Totale 7.331
Categoria #
all - tutte 25.086
article - articoli 23.327
book - libri 0
conference - conferenze 1.759
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.172


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202122 0 0 0 0 0 0 0 0 0 0 0 22
2021/2022424 31 136 8 38 10 7 5 28 28 7 36 90
2022/2023849 44 117 70 138 83 196 15 45 101 11 10 19
2023/2024406 18 25 39 29 57 88 19 31 5 27 52 16
2024/2025977 52 45 45 160 39 43 50 33 140 49 106 215
2025/20263.200 212 148 205 559 873 187 284 166 276 176 40 74
Totale 7.331